Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2011 3
2012 9
2013 34
2014 74
2015 104
2016 221
2017 255
2018 238
2019 272
2020 340
2021 394
2022 442
2023 402
2024 209

Text availability

Article attribute

Article type

Publication date

Search Results

2,659 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Wanner C, et al. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14. N Engl J Med. 2016. PMID: 27299675 Free article. Clinical Trial.
In the EMPA-REG OUTCOME trial, empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes at high risk for cardiovascular events. ...CONCLUSIONS: In patients with type 2 diab …
In the EMPA-REG OUTCOME trial, empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovas …
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
Filippatos G, Butler J, Farmakis D, Zannad F, Ofstad AP, Ferreira JP, Green JB, Rosenstock J, Schnaidt S, Brueckmann M, Pocock SJ, Packer M, Anker SD; EMPEROR-Preserved Trial Committees and Investigators. Filippatos G, et al. Circulation. 2022 Aug 30;146(9):676-686. doi: 10.1161/CIRCULATIONAHA.122.059785. Epub 2022 Jun 28. Circulation. 2022. PMID: 35762322 Free PMC article. Clinical Trial.
Empagliflozin reduced the rate of the primary outcome irrespective of diabetes status (hazard ratio, 0.79 [95% CI, 0.67, 0.94] for patients with diabetes versus hazard ratio, 0.78 [95% CI, 0.64, 0.95] in patients without diabetes; P(interaction)=0.92). …
Empagliflozin reduced the rate of the primary outcome irrespective of diabetes status (hazard ratio, 0.79 [95% CI, 0.67, 0.94] …
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rossing P, Scott C, Gay A, Agarwal R. Green JB, et al. Nephrol Dial Transplant. 2023 Mar 31;38(4):894-903. doi: 10.1093/ndt/gfac198. Nephrol Dial Transplant. 2023. PMID: 35700142 Free PMC article. Clinical Trial.
The primary objective is to demonstrate that 6 months of dual therapy comprising finerenone and the SGLT2i empagliflozin is superior for reducing albuminuria versus either agent alone. Interventions will be once-daily finerenone 10 mg or 20 mg (target dose) plus empagli …
The primary objective is to demonstrate that 6 months of dual therapy comprising finerenone and the SGLT2i empagliflozin is superior …
Empagliflozin, diabetes and outcomes.
[No authors listed] [No authors listed] Drug Ther Bull. 2016 Jul;54(7):78-81. doi: 10.1136/dtb.2016.6.0411. Drug Ther Bull. 2016. PMID: 27417322 Review.
The prevalence of type 2 diabetes is rising, and in 2015 more than 5% of adults in the UK were affected by this condition.(1,2) Management of type 2 diabetes includes encouraging lifestyle changes (increased exercise, modification of diet and smoking cessation) alon …
The prevalence of type 2 diabetes is rising, and in 2015 more than 5% of adults in the UK were affected by this condition.(1,2) Manag …
Diabetes Mellitus and Heart Failure.
Lehrke M, Marx N. Lehrke M, et al. Am J Med. 2017 Jun;130(6S):S40-S50. doi: 10.1016/j.amjmed.2017.04.010. Am J Med. 2017. PMID: 28526183 Free article. Review.
Epidemiologic and clinical data from the last 2 decades have shown that the prevalence of heart failure in diabetes is very high, and the prognosis for patients with heart failure is worse in those with diabetes than in those without diabetes. ...In addition, …
Epidemiologic and clinical data from the last 2 decades have shown that the prevalence of heart failure in diabetes is very high, and …
Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota.
Deng L, Yang Y, Xu G. Deng L, et al. Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Dec;1867(12):159234. doi: 10.1016/j.bbalip.2022.159234. Epub 2022 Sep 19. Biochim Biophys Acta Mol Cell Biol Lipids. 2022. PMID: 36185030
BACKGROUND: The dysregulation of gut microbiota can be found in patients with type 2 diabetes mellitus (T2DM)-related diabetic nephropathy (DN). Inhibitors of sodium-glucose co-transporter 2 (SGLT2) were reported to affect gut microbiota. This study aimed to …
BACKGROUND: The dysregulation of gut microbiota can be found in patients with type 2 diabetes mellitus (T2DM)-related diabe …
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.
Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsäßer A, Ritter I, Steubl D, Wanner C, Wheeler DC. Tuttle KR, et al. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034. Diabetes Care. 2022. PMID: 35472672 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the safety of empagliflozin in patients with type 2 diabetes and moderate to severe chronic kidney disease (CKD) (category G3-4) enrolled in clinical trials. ...Notably lower risks were observed in both groups for hyperkalemia (hazard ratio 0.59 …
OBJECTIVE: To assess the safety of empagliflozin in patients with type 2 diabetes and moderate to severe chronic kidney diseas …
Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.
Halden TAS, Kvitne KE, Midtvedt K, Rajakumar L, Robertsen I, Brox J, Bollerslev J, Hartmann A, Åsberg A, Jenssen T. Halden TAS, et al. Diabetes Care. 2019 Jun;42(6):1067-1074. doi: 10.2337/dc19-0093. Epub 2019 Mar 12. Diabetes Care. 2019. PMID: 30862658 Clinical Trial.
OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have lately become the recommended treatment in patients with type 2 diabetes and high cardiovascular risk. Patients with posttransplant diabetes mellitus (PTDM) also have high cardiovascular risk. …
OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have lately become the recommended treatment in patients with type 2 diabete …
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA. Verma S, et al. Circulation. 2019 Nov 19;140(21):1693-1702. doi: 10.1161/CIRCULATIONAHA.119.042375. Epub 2019 Aug 22. Circulation. 2019. PMID: 31434508 Clinical Trial.
We sought to determine if empagliflozin causes a decrease in left ventricular (LV) mass in people with type 2 diabetes mellitus and coronary artery disease. ...CONCLUSIONS: Among people with type 2 diabetes mellitus and coronary artery disease, …
We sought to determine if empagliflozin causes a decrease in left ventricular (LV) mass in people with type 2 diabetes mell …
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study.
Lim J, Choi YJ, Kim BS, Rhee TM, Lee HJ, Han KD, Park JB, Na JO, Kim YJ, Lee H, Kim HK. Lim J, et al. Cardiovasc Diabetol. 2023 Jul 26;22(1):188. doi: 10.1186/s12933-023-01911-7. Cardiovasc Diabetol. 2023. PMID: 37496050 Free PMC article.
Thus, we compared the cardiovascular outcomes between new users of dapagliflozin and empagliflozin in a broad range of patients with type 2 diabetes mellitus using a nationwide population-based real-world cohort from Korea. ...Approximately 40% of the patient …
Thus, we compared the cardiovascular outcomes between new users of dapagliflozin and empagliflozin in a broad range of patients with …
2,659 results

Searches related to "empagliflozin diabetes"